Hydroxyurea in children with sickle cell disease: practice patterns and barriers to utilization.
about
Technology Access and Smartphone App Preferences for Medication Adherence in Adolescents and Young Adults With Sickle Cell Disease.Do difficulties in swallowing medication impede the use of hydroxyurea in children?Treatment for sickle cell disease in Africa: should we invest in haematopoietic stem cell transplantation?Medication adherence among pediatric patients with sickle cell disease: a systematic review.National trends in incidence rates of hospitalization for stroke in children with sickle cell disease.Sickle cell disease: a neglected chronic disease of increasing global health importanceHydroxyurea use and hospitalization trends in a comprehensive pediatric sickle cell programSocioeconomic and demographic characteristics of sickle cell disease patients from a low-income region of northeastern BrazilHydroxyurea therapy for children with sickle cell disease: describing how caregivers make this decision.Rationale and design of mDOT-HuA study: a randomized trial to assess the effect of mobile-directly observed therapy on adherence to hydroxyurea in adults with sickle cell anemia in Tanzania.Impact of hydroxyurea on clinical events in the BABY HUG trial.Parental and other factors associated with hydroxyurea use for pediatric sickle cell diseaseHydroxyurea down-regulates BCL11A, KLF-1 and MYB through miRNA-mediated actions to induce γ-globin expression: implications for new therapeutic approaches of sickle cell diseaseA systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell diseaseHydroxyurea use in sickle cell disease: the battle with low prescription rates, poor patient compliance and fears of toxicities.Monitoring toxicity, impact, and adherence of hydroxyurea in children with sickle cell disease.Enrichment of human hematopoietic stem/progenitor cells facilitates transduction for stem cell gene therapy.Shared decision making for hydroxyurea treatment initiation in children with sickle cell anemia.Health-related quality of life in sickle cell disease: past, present, and future.Quality and safety in pediatric hematology/oncology.Decreased fetal hemoglobin over time among youth with sickle cell disease on hydroxyurea is associated with higher urgent hospital use.Improvement of medical care in a cohort of newborns with sickle-cell disease in North Paris: impact of national guidelines.Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease.rs11886868 and rs4671393 of BCL11A associated with HbF level variation and modulate clinical events among sickle cell anemia patients.Hydroxyurea in Pediatric Patients With Sickle Cell Disease: What Nurses Need to Know.From trust to skepticism: An in-depth analysis across age groups of adults with sickle cell disease on their perspectives regarding hydroxyurea.High resource hospitalizations among children with vaso-occlusive crises in sickle cell disease
P2860
Q33447034-C8A5EF4E-8D8B-4C75-BAE5-21196A92F87EQ34285113-9D4337BF-79FF-4BE9-A49C-825C986F69D0Q34431739-6C428778-EA56-4C4E-8436-DCC06A71F843Q34567690-263B7E09-CDB0-4048-87F9-C8BE6D9F45F2Q34601055-104871E5-3973-4644-8758-09241E7D8B63Q34852524-DABE1F6A-797E-4E5D-B86A-9D49E92EA723Q34964869-4438F5DF-6B59-4066-B706-3CCB9926A836Q35693975-5203F0B7-00C6-42E8-B19B-BAF465D22007Q35754065-6B30C27B-F859-4DB0-AF1B-B5486F5EEA24Q36166540-0ADA13DF-CB50-46BB-AE84-E2C3CF3D55E8Q36425423-1E7928AA-1B4C-46C8-B4FB-734FE73B6C47Q36763705-5F81A0A2-B3A1-4D22-9EFF-3BD8B2E70617Q36777717-68A65176-0D63-46D6-9B5D-79055AF0C7CDQ36792555-32459113-FDDE-4BC6-83E3-6E939D0D5156Q37223344-794D22C9-4F5C-469B-85B2-562FA32EC304Q37244000-2FADF766-4C51-4216-9EFA-219A650D657FQ37358032-118A9DD1-3494-4141-8D95-2E782F90EC4DQ37612822-6B884E2E-4412-43D5-A99F-5765FEFE1571Q38004362-BB70677C-ECDB-48FB-BDEB-9788CD7E23EDQ38183751-0134B9B5-BD76-4FEF-8BDC-3BC59CAA4AA2Q39442230-8F8401C0-35B3-43FD-B71D-AEA309D0C8E0Q40721306-ED3F2432-CC99-44E5-B7FE-553FFF79937EQ41983509-09CCE6CE-ABC7-4D40-A49F-61E9341A6830Q46716752-A36E3276-EF6C-4846-BCA4-AFB7BAA44514Q47955242-DD393852-5E43-4C1A-8413-5D8C8791FF3FQ55513319-1CEAE907-0AFF-4269-A760-9DDC0DBE03C8Q58883327-83F73B02-5C82-4112-BAFA-9279A1DE8670
P2860
Hydroxyurea in children with sickle cell disease: practice patterns and barriers to utilization.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Hydroxyurea in children with s ...... s and barriers to utilization.
@ast
Hydroxyurea in children with s ...... s and barriers to utilization.
@en
Hydroxyurea in children with s ...... s and barriers to utilization.
@nl
type
label
Hydroxyurea in children with s ...... s and barriers to utilization.
@ast
Hydroxyurea in children with s ...... s and barriers to utilization.
@en
Hydroxyurea in children with s ...... s and barriers to utilization.
@nl
prefLabel
Hydroxyurea in children with s ...... s and barriers to utilization.
@ast
Hydroxyurea in children with s ...... s and barriers to utilization.
@en
Hydroxyurea in children with s ...... s and barriers to utilization.
@nl
P2093
P2860
P356
P1476
Hydroxyurea in children with s ...... s and barriers to utilization.
@en
P2093
Amanda M Brandow
Danielle L Jirovec
Julie A Panepinto
P2860
P304
P356
10.1002/AJH.21749
P577
2010-08-01T00:00:00Z